<DOC>
	<DOCNO>NCT00870103</DOCNO>
	<brief_summary>To demonstrate combination formulation Moxifloxacin/Dexamethasone Eye Drop effective safe prevention postoperative inflammation consequence cataract extraction surgery .</brief_summary>
	<brief_title>Study Efficacy Safety Vigadexa Treating Inflammation Infection Post-cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>≧18 year age able sign inform consent complete require visit intend cataract extraction surgery follow implantation posterior chamber Intraocular lens ( IOL ) Intraocular Pressure ( IOP ) ≦ 20 millimeter mercury ( mmHg ) Uncontrolled glaucoma IOP use ocular antiinfectious study within 30 day prior enrollment , secondary implantation replacement IOL study eye use steroid study within 14 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Cataract</keyword>
</DOC>